

George L Chen

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5763179/publications.pdf>

Version: 2024-02-01

52
papers

738
citations

623734

14
h-index

552781

26
g-index

53
all docs

53
docs citations

53
times ranked

1415
citing authors

#	ARTICLE	IF	CITATIONS
1	Late Acute and Chronic Graft-versus-Host Disease after Allogeneic Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 449-455.	2.0	113
2	Infection Rates among Acute Leukemia Patients Receiving Alternative Donor Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 1636-1645.	2.0	71
3	A Randomized Phase II Crossover Study of Imatinib or Rituximab for Cutaneous Sclerosis after Hematopoietic Cell Transplantation. <i>Clinical Cancer Research</i> , 2016, 22, 319-327.	7.0	68
4	X-linked clonality testing: interpretation and limitations. <i>Blood</i> , 2007, 110, 1411-1419.	1.4	55
5	Housing Temperature-Induced Stress Is Suppressing Murine Graft-versus-Host Disease through β 2-Adrenergic Receptor Signaling. <i>Journal of Immunology</i> , 2015, 195, 5045-5054.	0.8	48
6	Late acute graft-versus-host disease: a prospective analysis of clinical outcomes and circulating angiogenic factors. <i>Blood</i> , 2016, 128, 2350-2358.	1.4	43
7	A phase 1 study of imatinib for corticosteroid-dependent/refractory chronic graft-versus-host disease: response does not correlate with anti-PDGFR α antibodies. <i>Blood</i> , 2011, 118, 4070-4078.	1.4	40
8	Nonrelapse mortality among patients diagnosed with chronic GVHD: an updated analysis from the Chronic GVHD Consortium. <i>Blood Advances</i> , 2021, 5, 4278-4284.	5.2	36
9	T Cell-Derived CD70 Delivers an Immune Checkpoint Function in Inflammatory T Cell Responses. <i>Journal of Immunology</i> , 2017, 199, 3700-3710.	0.8	34
10	Amphiregulin modifies the Minnesota Acute Graft-versus-Host Disease Risk Score: results from BMT CTN 0302/0802. <i>Blood Advances</i> , 2018, 2, 1882-1888.	5.2	27
11	Granzyme B-Mediated Activation-Induced Death of CD4+ T Cells Inhibits Murine Acute Graft-versus-Host Disease. <i>Journal of Immunology</i> , 2015, 195, 4514-4523.	0.8	21
12	Employment, Insurance, and Financial Experiences of Patients with Chronic Graft-versus-Host Disease in North America. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 599-605.	2.0	20
13	Disability Related to Chronic Graft-versus-Host Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 772-777.	2.0	16
14	Anti-Platelet-Derived Growth Factor Receptor Alpha Chain Antibodies Predict for Response to Nilotinib in Steroid-Refractory or -Dependent Chronic Graft-Versus-Host Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 373-380.	2.0	15
15	Identification of Neurotoxicity after Chimeric Antigen Receptor (CAR) T Cell Infusion without Deterioration in the Immune Effector Cell-Associated Encephalopathy (ICE) Score. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, e271-e274.	2.0	13
16	Host-Derived CD70 Suppresses Murine Graft-versus-Host Disease by Limiting Donor T Cell Expansion and Effector Function. <i>Journal of Immunology</i> , 2017, 199, 336-347.	0.8	11
17	Remestemcel-L for acute graft-versus-host disease therapy. <i>Expert Opinion on Biological Therapy</i> , 2014, 14, 261-269.	3.1	10
18	Carfilzomib for Treatment of Refractory Chronic Graft-versus-Host Disease: A Chronic GVHD Consortium Pilot Phase II Trial. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 278-284.	2.0	10

#	ARTICLE	IF	CITATIONS
19	Reduced-Intensity Conditioning with Fludarabine, Melphalan, and Total Body Irradiation for Allogeneic Hematopoietic Cell Transplantation: The Effect of Increasing Melphalan Dose on Underlying Disease and Toxicity. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 689-698.	2.0	9
20	Dextramer reagents are effective tools for quantifying CMV antigen-specific T cells from peripheral blood samples. , 2014, , n/a-n/a.		8
21	Design and Patient Characteristics of the Chronic Graft-versus-Host Disease Response Measures Validation Study. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 1727-1732.	2.0	8
22	Initial therapy for chronic graft-versus-host disease: analysis of practice variation and failure-free survival. <i>Blood Advances</i> , 2021, 5, 4549-4559.	5.2	8
23	Clinical Experience in the Randomized Phase 3 Sierra Trial: Anti-CD45 Iodine (131I) Apamistamab [Iomab-B] Conditioning Enables Hematopoietic Cell Transplantation with Successful Engraftment and Acceptable Safety in Patients with Active, Relapsed/Refractory AML Not Responding to Targeted Therapies. <i>Blood</i> , 2021, 138, 1791-1791.	1.4	6
24	Impact of Molecular Features of Diffuse Large B-Cell Lymphoma on Treatment Outcomes with Anti-CD19 Chimeric Antigen Receptor (CAR) T-Cell Therapy. <i>Blood</i> , 2021, 138, 165-165.	1.4	6
25	Early versus Late Preemptive Allogeneic Hematopoietic Cell Transplantation for Relapsed or Refractory Acute Myeloid Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 1369-1374.	2.0	5
26	Quantifying MHC dextramer-induced NFAT activation in antigen-specific T cells as a functional response parameter. <i>Methods</i> , 2017, 112, 75-83.	3.8	5
27	The Chronic Graft-versus-Host Disease Failure-Free Survival (cGVHD-FFS) Index. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 2468-2473.	2.0	4
28	Immune profiling in diffuse large B-cell lymphoma and mantle cell lymphoma patients treated with autologous hematopoietic cell transplant. <i>Bone Marrow Transplantation</i> , 2020, 55, 77-85.	2.4	4
29	Low-Level Cytomegalovirus Antigenemia Promotes Protective Cytomegalovirus Antigen-Specific T Cells after Allogeneic Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 2147-2154.	2.0	4
30	Optimizing the Timing of Allogeneic Blood or Marrow Transplantation (BMT) in a Prospective Cohort of Relapsed or Refractory Acute Myeloid Leukemia (AML). <i>Blood</i> , 2011, 118, 3096-3096.	1.4	4
31	̢2- Adrenergic Signaling Regulates Graft Versus Host Disease after Allogeneic Transplantation While Preserving Graft Versus Leukemia Effect. <i>Blood</i> , 2019, 134, 1915-1915.	1.4	3
32	IgG Allotypes Reveal That Antimicrobial Humoral Immunity Persists after Reduced-Intensity Hematopoietic Cell Transplantation. <i>Blood</i> , 2008, 112, 349-349.	1.4	3
33	BPX-501 T cells interfere with minimal residual disease evaluation of B-cell acute lymphoblastic leukemia. <i>Bone Marrow Transplantation</i> , 2018, 53, 651-653.	2.4	2
34	Optical Coherence Tomography for Quantifying Human Cutaneous Chronic Graft-versus-Host Disease. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 271.e1-271.e8.	1.2	2
35	Equate, a Phase 1b/2 Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of a Novel Targeted Anti-CD6 Therapy, Itolizumab, in Subjects with Newly Diagnosed Acute Graft Versus Host Disease. <i>Blood</i> , 2019, 134, 4516-4516.	1.4	2
36	Organ Changes Associated with Provider-Assessed Responses in Patients with Chronic Graft-versus-Host Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 1869-1874.	2.0	1

#	ARTICLE	IF	CITATIONS
37	Replicated Risk Index of Patient Functional Status Prior to Allogeneic Hematopoietic Cell Transplantation Predicts Healthcare Utilization and Survival. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 875.e1-875.e9.	1.2	1
38	Rituximab Infusion Two Months after HCT Decreases Alloreactive B Cell Responses While Recipient Plasma Cells Persist.. <i>Blood</i> , 2008, 112, 2234-2234.	1.4	1
39	Effect of Immune Reconstitution on Survival after Autologous Hematopoietic Cell Transplant for B-Cell Non-Hodgkin Lymphoma. <i>Blood</i> , 2015, 126, 3173-3173.	1.4	1
40	Tlr4 Is Monoallelically Expressed in Human BFU-E and CFU-E and May Have Application as a Clonality Marker in Hematological Disorders Due to Somatic Mutations in Both Males and Females.. <i>Blood</i> , 2006, 108, 3619-3619.	1.4	0
41	Identification of a Homeobox-Like Protein Immune Response in Bone Marrow Transplant Patients. <i>Blood</i> , 2008, 112, 4856-4856.	1.4	0
42	Post Transplant Allogeneic Antibody Responses Form against Annexin 8. <i>Blood</i> , 2008, 112, 4605-4605.	1.4	0
43	A Dose Escalation Trial of Imatinib for Steroid Dependent Chronic Graft-Versus-Host Disease with Anti-PDGFRA Antibody Analysis.. <i>Blood</i> , 2009, 114, 3304-3304.	1.4	0
44	Fludarabine, Melphalan and Low Dose Total Body Irradiation for Reduced Intensity Conditioning (RIC) Prior to Allogeneic Hematopoietic Cell Transplantation (AlloHCT). <i>Blood</i> , 2011, 118, 4570-4570.	1.4	0
45	Micro Dose Methotrexate (MTX) Is Equivalent to Full Dose MTX and Superior to No MTX for Acute Graft-Versus-Host Disease Prophylaxis. <i>Blood</i> , 2011, 118, 3038-3038.	1.4	0
46	A Phase 1 Open Label, Dose Escalation Study of Nilotinib in Steroid Dependent/Refractory Chronic Graft-Versus-Host Disease. <i>Blood</i> , 2011, 118, 1986-1986.	1.4	0
47	Short Course of Levofloxacin During Neutropenia Prevents Early and Late Bacteremia Episodes After Allogeneic Blood and Marrow Transplantation (alloBMT). <i>Blood</i> , 2012, 120, 4141-4141.	1.4	0
48	Perforin Is Important For Both CD4+ and CD8+ T Cell-Mediated Graft-Versus-Tumor Effect But Plays Differential Roles In CD4+ and CD8+ T Cell Expansion After Allogeneic Transplantation. <i>Blood</i> , 2013, 122, 3255-3255.	1.4	0
49	Analysis Of Immune Cell Populations Before and After Autologous Hematopoietic Stem Cell Transplant For Multiple Myeloma: Association With Early Recovery Of Absolute Lymphocyte Count and Progression-Free Survival. <i>Blood</i> , 2013, 122, 3348-3348.	1.4	0
50	Identification of Immune Phenotypes Associated with Improved Progression Free and Overall Survival for Patients with Multiple Myeloma Treated with Autologous Hematopoietic Cell Transplantation. <i>Blood</i> , 2016, 128, 3454-3454.	1.4	0
51	Impact of conditioning regimen on peripheral blood hematopoietic cell transplant. <i>World Journal of Clinical Oncology</i> , 2019, 10, 86-97.	2.3	0
52	Age, Sex and Self-Reported Race Differences in Immune Profiles of Hematologic Malignancy Patients. <i>Blood</i> , 2021, 138, 4066-4066.	1.4	0